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Here, we present a report of the 2014 annual Beatson International Cancer Conference, Glasgow, July 6–9, 2014.
The theme was “Powering the Cancer Machine”, focusing on oncogenic signals that regulate metabolic rewiring
and the adaptability of the metabolic network in response to stress.
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Isocitrate dehydrogenase (IDH) mutations are found in a
variety of cancers including acute myeloid leukaemia.
IDH1 normally interconverts isocitrate and α-ketoglutarate
(αKG). The mutant isoform, expressed in a subset of
gliomas and acute myeloid leukaemias, instead converts
isocitrate to the non-degradable 2-hydroxyglutarate (2HG).
William Kaelin (Dana-Farber Cancer Institute) showed that
expression of the R132H mutant IDH1 drives growth
factor-independent proliferation of TF-1 leukaemia cells,
which are otherwise dependent on GM-CSF. He further
demonstrated that (R)-2HG, the enantiomer produced by
the R132H IDH mutant, could also support GM-CSF-
independent growth. It was found that (R)-2HG and (S)-
2HG differentially interact with a class of enzymes that
use αKG as a co-factor, including JmjC, Tet, PHD and
EglN family proteins, through which they elicit epigenetic
alterations and affect hypoxia-inducible factor (HIF) levels.
The mTOR pathway represents a central cellular
nutrient-sensing hub, which controls many aspects of
cellular metabolism. The tuberous sclerosis (TSC)
tumour suppressor proteins (TSC1 and TSC2) are in-
hibitors of mTOR activation. Michael Hall (University
of Basel) showed that deletion of TSC1 in the liver
drives mTORC1 hyperactivation, resulting in elevated
secretion of FGF21, a reduction in body temperature
and reduced nocturnal activity. Treatment of mice* Correspondence: Daniel.Murphy@glasgow.ac.uk
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normal body temperature and activity levels. These
studies represent a novel observation that mTOR acti-
vation could reduce body temperature, while previous
studies have shown that mTOR inhibition by rapamy-
cin could affect body size and prolong lifespan.
David Sabatini (Whitehead Institute, MIT), who dis-
covered mTOR while a graduate student with Solomon
Snyder at Johns Hopkins, discussed cell-autonomous
regulation of TORC1 and focused specifically on amino
acid sensing by the TORC1 pathway. In the presence of
amino acids, TORC1 is recruited to lysosomes via Rag
GTPase heterodimers. However, neither the Rag proteins
themselves nor their guanine nucleotide exchange factor,
Ragulator, directly bind to amino acids. The amino
acid-sensing component of the pathway likely resides
within the lysosome, where amino acids are concentrated
up to millimolar levels.Metabolic signalling
It has been documented that MYC drives the Warburg
effect, which describes the propensity for cancer cells to
import large amounts of glucose and excrete most of it
as lactate. Lactate is transported through monocarboxyl-
ate transporters (MCTs). John Cleveland (Moffitt Cancer
Center) documented that MYC could directly induce the
expression of MCT1 (SLC16A1) and discussed the
therapeutic potential of MCT1 inhibition in the context
of MYC-driven breast cancer and Burkitt’s lymphoma.
MCT1 inhibition suppresses activity of the lower half
of the glycolytic pathway and glutathione production,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(ROS). MCT1 inhibition moreover suppresses the Cori
cycle, through which lactate is removed from the circu-
lation by the liver and used to drive gluconeogenesis.
Treatment with the MCT1 inhibitor thus lowers circu-
lating glucose and lactate, suggesting an additional use
for such agents to treat type II diabetes.
The cell’s energetic state is continuously monitored by
the AMP-activated protein kinase AMPK, which re-
sponds dynamically to changes in the ATP:AMP ratio in
order to suppress anabolism and promote catabolic ac-
tivity, thereby maintaining energetic homeostasis. Daniel
Murphy (University of Glasgow) spoke of exploiting this
feedback mechanism as a strategy for targeting MYC in
cancer. MYC accelerates ATP consumption, resulting in
progressive activation of AMPK. Surprisingly, a related
kinase ARK5 (aka NUAK1) is required for efficient acti-
vation of AMPK by MYC, and depletion of either is syn-
thetically lethal with MYC overexpression. Inhibition of
ARK5 acutely perturbs mitochondrial respiration, and
genetic experiments suggest that targeting ARK5 may
be effective against some forms of colorectal cancer.
Reuben Shaw (Salk Institute) discussed an affinity trap
strategy for isolation of physiological targets of AMPK
using a SILAC approach adapted for use in vivo and
noted that AMPKα1/α2 double-knockout cells also exhibit
mitochondrial defects. Consistent with this observation, D.
Grahame Hardie (University of Dundee) stressed that pro-
motion of glycolysis by AMPK is an acute phenomenon
whereas sustained activation promotes oxidative phosphor-
ylation. As a negative regulator of TORC1-driven cell
growth, AMPK is implicated in tumour suppression and
may thus serve different roles at different stages of tumour
development. Recent reports that AMPK can be activated
by binding to ADP, as well as to AMP, were discussed as
were arguments against a major contribution by ADP levels
to AMPK regulation under physiological conditions.
Owen Sansom (Beatson Institute) discussed perturba-
tions to mTORC1 signal transduction in APC-deleted
intestinal epithelium. Loss of APC leads to deregulated
β-catenin activity and consequently to elevation of MYC
expression. In intestinal epithelium, this correlates with
increased mTORC1 activity, as evidenced by elevated
levels of phospho-S6K and phospho-4E-BP1, and MYC
deletion coincident with APC loss restores mTORC1
activity to normal. Treatment of floxed APC mice with
rapamycin reversibly prevents tumour progression in the
intestine whereas mutation of KRas in combination with
APC loss is associated with resistance to rapamycin.
Increased protein translation in tumour cells generates
its own limitations as cells struggle to maintain the
required supply of amino acids. Brendan Manning
(Harvard University) presented evidence that TORC1 de-
regulation simultaneously drives increased protein turnoveras well as increased protein production and both effects are
sensitive to rapamycin. Accordingly, cells with deregulated
mTORC1 are selectively sensitive to bortezomib-mediated
inhibition of the 40S proteasome. SREBP1 activation down-
stream of TORC1 drives NRF1-mediated coordinated tran-
scription of proteasome subunits in a pre-programmed
adaptive response to anabolic stress.
Macropinocytosis, a process associated with Ras mutation
through which cells absorb nutrients in bulk, may reflect
another mechanism to replenish amino acid levels. Dafna
Bar-Sagi (New York Langone Medical Center) described re-
cent work on the role of macropinocytosis in tumour me-
tabolism. Using a combination of microscopy and isotope
tracing, it was found that macropinocytosis enables the
consumption and degradation of extracellular protein to
support metabolism. Various aspects of the significance of
this novel mode of eating were discussed.
In addition to its roles in driving increased protein
translation and elongation, John Blenis (Weill Cornell
Medical College) presented evidence that TORC1 also
regulates splicing efficiency. Downstream of TORC1, re-
cruitment of S6K1, but not S6K2, occurs to the exon
junction complex via specific interaction with SKAR
(polymerase delta-interacting protein 3). Recruitment of
both factors is required for the efficient expression of
intron-containing pre-mRNAs.
Reactive Oxygen species (ROS) play a complex role in
tumourigenesis being at once mutagenic and cytotoxic,
depending on levels. Boudewijn Burgering (UMC, Utrecht)
discussed direct sensing of ROS by Forkhead transcription
factors via oxidation of cysteine residues, allowing the for-
mation of stable intermolecular disulfide bridges between
FOXO and other proteins, such as p300. Treatment of cells
with hydrogen peroxide drives FOXO into the nucleus,
activating a transcription programme to counteract ROS.Metabolic pathways and stress
As reported earlier, HIFs play an important role in tumour
progression. While in gliomas and leukaemias HIF levels
are affected by 2HG, in clear cell renal cell carcinoma
(ccRCC), HIF1α is stabilised by loss-of-function of the
Von Hippel-Lindau (VHL) protein. A newly discovered
mechanism of HIF activation in ccRCC was presented by
Celeste Simon (University of Pennsylvania), who discussed
the role of the gluconeogenic enzyme fructose-1,6-bispho-
sphatase 1 (FBP1). This enzyme is almost uniformly de-
pleted in 600 ccRCC tumours examined. FBP1 opposes
aerobic glycolysis in renal tubular epithelial cells. Un-
expectedly, FBP1 was also found to inhibit nuclear HIF
function in a non-canonical fashion by interacting with its
inhibitory domain. Loss of FBP1 therefore may collaborate
with the prominent VHL mutations in ccRCC to promote
HIF activation and thus tumour growth.
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stressful conditions of the tumour microenvironment.
Ralph DeBerardinis (University of Texas, Southwestern)
therefore emphasised the need for protocols for
in vivo isotope tracing. A case study was shown where
human glioblastoma (GBM) patients were infused with
13C-glucose prior to excision of their tumour and
analysis. Using this approach, it was found that in vivo,
GBM tumours consistently had surprisingly high pyru-
vate dehydrogenase and hence citric acid cycle activity,
driving net production of glutamate.
The enzyme phosphoglycerate dehydrogenase (PHGDH)
catalyses the first step in the conversion of the glycolytic
intermediate 3-phosphoglycerate to serine and glycine.
PHGDH has been found to be amplified or overex-
pressed in a variety of cancers, indicating the import-
ance of these amino acids in cancer cell proliferation.
While serine and glycine can be interconverted by
serine hydromethyl transferases (SHMT 1 and 2), the
relative importance of these amino acids in tumour
growth remains unclear. Oliver Maddocks (Beatson
Institute) showed that only serine rescued reduced
proliferation of cancer cells in medium lacking both
serine and glycine. This corroborated the finding that
most cell lines avidly consume exogenous serine and
only uptake glycine when serine depletes. Serine plays
an important role in folate metabolism, supplying one-
carbon units for purine nucleotide synthesis.
Anne Brunet (Stanford University) discussed the meta-
bolic regulation of aging using the C. elegans model. She
focused on histone methylation as deficiencies in tri-
methylation of histone 3 at lysine 4 (H3K4me3) were
found to increase lifespan. Regulation of H3K27me3 was
also involved in lifespan determination. Brunet further
discussed the importance of fat metabolism, in particular
the different type of fatty acids, in H3K4me3-deficient
worms and how this relates to longevity.
Autophagy is a cellular degradation pathway that can,
depending on the context, have a tumour-suppressing or
tumour-promoting role. Alec Kimmelman (Dana-Farber
Cancer Institute) explained how this role of autophagy
in cancer depends on both the type and timing of
genetic alterations that occur. Recent experiments in a
genetically engineered mouse model of pancreatic cancer
(PDAC) with oncogenic KRas and homozygous loss of
Trp53 showed that loss of autophagy accelerated tumour
progression. Kimmelman showed that in a similar mouse
model with instead sporadic LOH of Trp53, tumour
growth was dependent on autophagy. In this setting,
autophagy may promote tumour progression by main-
taining metabolic homeostasis during nutrient starva-
tion. Kimmelman further described how specific cargo is
targeted for selective autophagy. Nuclear receptor co-
activator 4 (NCOA4) was found to be highly enriched inlysosomes where it acts as a selective cargo receptor for
turnover of ferritin to sustain iron homeostasis.
Daniel Peeper (Netherlands Cancer Institute) discussed
a surprising role for pyruvate dehydrogenase kinase 1
(PDK1) in suppressing oncogene-induced senescence
(OIS) in BRafV600E-driven melanoma. Pyruvate dehydro-
genase is rate limiting for entry of pyruvate into the TCA
cycle and contributes to maintenance of senescence in
pre-neoplastic nevi. Forced expression of PDK1 inhibits
PDH, bypasses OIS and thereby facilitates progression to
melanoma. Importantly, suppression of PDK combines
with paclitaxel to drive regression of established
melanomas.
Therapeutic opportunities
Susan Critchlow (AstraZeneca) described efforts to tar-
get MCTs. As reported above, MYC induces MCT1
while HIF1 could activate the expression of MCT4.
Given that the tumour microenvironment permits the
commensal existence of hypoxic cells that export lactate
and respiring cells that could import lactate for oxida-
tion, inhibition of MCTs would be of therapeutic inter-
est. Highly glycolytic tumour cells depend on these
transporters to export rapidly produced lactate. Inhib-
ition of MCT1 with a novel small molecule (AZD3965)
decreased the proliferation rate of Raji Burkitt lymph-
oma cells, both in vitro and in vivo. These observations
are consistent with the work of John Cleveland.
Chi Van Dang (University of Pennsylvania) provided a
background on the MYC oncogene and briefly discussed
two recent publications from the Amati and Eilers
groups in support of the case that MYC does indeed
have specific transcriptional targets. He provided a con-
ceptual framework for oncogene-dependent nutrient
addiction, reasoning that constitutive activation of growth
factor-independent cell growth and proliferation would
render cancer cells addicted to nutrients to support
deregulated growth. He also showed that MYC-dependent
transformation systems are dependent on both glucose
and glutamine, hence causing MYC-dependent cancers to
be sensitive to inhibition of glycolytic and glutaminolytic
enzymes. This was demonstrated by using lactate
dehydrogenase A (LDHA) as an example. He further
reported that survival in a transgenic model of MYC-
dependent liver cancer could be prolonged by treatment
with BPTES, an inhibitor of glutaminase.
Pharmaceutical efforts to target mutant IDH already
provide clinical proof of concept that acute myelogenous
leukaemia could be treated in humans in phase I studies.
Katharine Yen (Agios) showed that targeting mutant
IDH can provide clinical benefit. Mutant IDH1/2 drives
2HG accumulation, leading to histone and DNA hyper-
methylation, suppressing hematopoietic differentiation.
Inhibitors of mutant IDH were able to reverse this
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kaemia models, resulting in significant survival benefit,
in vivo.
Although cancer cells have been shown to use glucose
and glutamine, alternative nutrient sources are less well
understood. Eyal Gottlieb (Beatson Institute) discussed
the role of acetate metabolism in hypoxic cancer cells.
Hypoxia limits production of acetyl-CoA from glucose,
which is largely converted to lactate through anaerobic
glycolysis. By using siRNA screens, it was found that
acetyl-CoA synthetase 2 (ACSS2), which catalyses the
production of acetyl-CoA from acetate, was essential for
cellular growth in hypoxic and nutrient-stressed condi-
tions. ACSS2 is highly amplified in breast cancer, and
further investigation confirmed the role of ACSS2 in
driving acetate consumption for fatty acid synthesis.
Silencing of ACSS2 suppresses cancer cell growth, both
in vitro and in vivo. Thus, ACSS2 could be an attractive
therapeutic target.
Conclusion
The conference provided the audience a broad sampling
of up-to-date knowledge and state-of-the-art techno-
logical developments. Next year’s Beatson Conference
will be between the 5th and 8th of July, and its theme will
be Control of Cell Polarity and Movement in Cancer.
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